BioLineRx and Hemispherian presented data at ESMO 2026 showing that GLIX1 works synergistically with multiple PARP inhibitors in HR-proficient ovarian cancer cell lines and patient-derived xenograft models. The combination of low-dose GLIX1 and olaparib significantly inhibited tumor growth, comparable to the chemotherapy drug cisplatin. This suggests GLIX1 could enhance the effectiveness of existing PARP inhibitor therapies, potentially improving outcomes for ovarian cancer patients. Further clinical development is anticipated to explore this promising combination.
BioLineRx and Hemispherian's preclinical data on GLIX1 synergy with PARP inhibitors provides context for health sector activity. For readers following health stocks, of 150 priced US health-sector stocks on Pluang, 51 rose and 90 fell today. Notable movers include NUWE at USD 0.53 with a 7.63% gain and 100% buy orders, TNGX at USD 29.25 up 4.73% with 100% buy orders, and MRNA at USD 193.84 down 4.34% with 71% sell orders. Data is as of Oct 23, 2026 17:11 WIB.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
